Literature DB >> 25297801

Molecular markers for colon diagnosis, prognosis and targeted therapy.

Daniel O Herzig1, Vassiliki L Tsikitis.   

Abstract

Colorectal adenocarcinoma (CRC), the second leading cancer-related death in the United States, remains a global public health issue. Sporadic CRC is considered the result of sequential mucosal changes from normal colonic mucosa to adenocarcinoma. Efforts in understanding the molecular pathways leading to CRC tumorigenesis may lead to identifying novel, individually tailored therapeutic targets for patients. In this review, we focus on well-published prognostic and predictive markers in CRC and examine their role in clinical practice.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRAF V600E; KRAS; MSI; PI3K; TP53

Mesh：

Substances：

Year:  2014        PMID： 25297801     DOI： 10.1002/jso.23806

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  21 in total

1.  Comparing Artificial Intelligence Platforms for Histopathologic Cancer Diagnosis.

Authors:  Andrew A Borkowski; Catherine P Wilson; Steven A Borkowski; L Brannon Thomas; Lauren A Deland; Stefanie J Grewe; Stephen M Mastorides
Journal:  Fed Pract       Date:  2019-10

2.  The Effects of Different mTOR Inhibitors in EGFR Inhibitor Resistant Colon Carcinoma Cells.

Authors:  Tamás Sticz; Anna Molnár; Titanilla Dankó; Zoltán Hujber; Gábor Petővári; Noémi Nagy; Gyula Végső; László Kopper; Anna Sebestyén
Journal:  Pathol Oncol Res       Date:  2018-06-07       Impact factor: 3.201

Review 3.  [Molecular pathology of colorectal cancer].

Authors:  J H L Neumann; A Jung; T Kirchner
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

4.  Gene Copy Number and Post-Transductional Mechanisms Regulate TRAP1 Expression in Human Colorectal Carcinomas.

Authors:  Michele Pietrafesa; Francesca Maddalena; Luciana Possidente; Valentina Condelli; Pietro Zoppoli; Valeria Li Bergolis; Maria Grazia Rodriquenz; Michele Aieta; Giulia Vita; Franca Esposito; Matteo Landriscina
Journal:  Int J Mol Sci       Date:  2019-12-24       Impact factor: 5.923

5.  Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome.

Authors:  Eric R Fearon; John M Carethers
Journal:  Gastroenterology       Date:  2014-11-22       Impact factor: 22.682

6.  Microsatellite instability and B-type Raf proto-oncogene mutation in colorectal cancer: Clinicopathological characteristics and effects on survival.

Authors:  Sebnem Batur; Dogu Vuralli Bakkaloglu; Nuray Kepil; Sibel Erdamar
Journal:  Bosn J Basic Med Sci       Date:  2016-11-10       Impact factor: 3.363

Review 7.  Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy.

Authors:  Donatella Verbanac; Andrea Čeri; Iva Hlapčić; Mehdi Shakibaei; Aranka Brockmueller; Božo Krušlin; Neven Ljubičić; Neven Baršić; Dijana Detel; Lara Batičić; Lada Rumora; Anita Somborac-Bačura; Mario Štefanović; Ivana Ćelap; Alma Demirović; Roberta Petlevski; József Petrik; Marija Grdić Rajković; Andrea Hulina-Tomašković; Ivana Rako; Luciano Saso; Karmela Barišić
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

8.  Long Non-coding RNA CBR3 Antisense RNA 1 is Downregulated in Colorectal Cancer and Inhibits miR-29a-Mediated Cell Migration and Invasion.

Authors:  Mei Yang; Wenxi Chen; Haojie Liu; Liang Yu; Mingwu Tang; Yinghui Liu
Journal:  Mol Biotechnol       Date:  2022-02-02       Impact factor: 2.695

9.  Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients.

Authors:  Qian Zhang; Xiao-Qing Wang; Jie Wang; Shu-Jian Cui; Xiao-Min Lou; Bing Yan; Jie Qiao; Ying-Hua Jiang; Li-Jun Zhang; Peng-Yuan Yang; Feng Liu
Journal:  Oncotarget       Date:  2015-06-20

10.  Validation of suitable normalizers for miR expression patterns analysis covering tumour heterogeneity.

Authors:  C Morata-Tarifa; M Picon-Ruiz; C Griñan-Lison; H Boulaiz; M Perán; M A Garcia; J A Marchal
Journal:  Sci Rep       Date:  2017-01-04       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.